Company news

Zymeworks Inc. news in 2025

Zymeworks Inc.'s news releases, calls and decks from 2025, newest first.

View company

Zymeworks Announces Participation in Upcoming Conferences

December 2, 2025

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

November 18, 2025

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

November 18, 2025

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

November 17, 2025

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

November 6, 2025

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

October 23, 2025

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

October 16, 2025

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

October 13, 2025

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

October 9, 2025

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

October 8, 2025

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

September 2, 2025

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11, 2025

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 7, 2025

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

July 28, 2025

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

July 17, 2025

Life Sciences BC Announces 2025 Awards Winners, Honouring Excellence in Health Innovation

July 10, 2025

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

May 30, 2025

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

May 22, 2025

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

May 19, 2025

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

April 25, 2025

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

April 21, 2025

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

April 17, 2025

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

March 25, 2025

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

March 5, 2025

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

February 26, 2025

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

February 18, 2025

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

February 12, 2025

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

January 7, 2025

Calls in 2025

Decks in 2025